

QUT Digital Repository:
<http://eprints.qut.edu.au/>



Flegg, Jennifer and McElwain, Sean and Long, Robert (2008) *The use of hyperbaric oxygen therapy to treat chronic wounds: A review*. *Wound Repair and Regeneration*, 16(3). pp. 321-330.

© Copyright 2008 John Wiley and Sons



PERSPECTIVE ARTICLE

The use of hyperbaric oxygen therapy to treat chronic wounds: A review

Jennifer A. Thackham, BSc¹; D.L. Sean McElwain, PhD¹; Robert J. Long, MD²

1. School of Mathematical Sciences, Queensland University of Technology, Brisbane, Australia, and

2. The Wesley Centre for Hyperbaric Medicine, Brisbane, Australia

Reprint requests:

Jennifer A. Thackham, BSc, School of Mathematical Sciences, Queensland University of Technology, GPO Box 2434, Brisbane 4001, Australia.
Tel: 61-7-3138 1293;
Fax: 61-7-3138 2310;
Email: j.thackham@qut.edu.au

Manuscript received: June 6, 2007

Accepted in final form: November 19, 2007

DOI:10.1111/j.1524-475X.2008.00372.x

ABSTRACT

Chronic wounds, defined as those wounds which fail to proceed through an orderly process to produce anatomic and functional integrity, are a significant socioeconomic problem. A wound may fail to heal for a variety of reasons including the use of corticosteroids, formation of squamous cell carcinoma, persistent infection, unrelieved pressure, and underlying hypoxia within the wound bed. Hypoxia appears to inhibit the wound healing process by blocking fibroblast proliferation, collagen production, and capillary angiogenesis and to increase the risk of infection. Hyperbaric oxygen therapy (HBOT) has been shown to aid the healing of ulcerated wounds and demonstrated to reduce the risk of amputation in diabetic patients. However, the causal reasons for the response of the underlying biological processes of wound repair to HBOT, such as the up-regulation of angiogenesis and collagen synthesis are unclear and, consequently, current protocols remain empirical. Here we review chronic wound healing and the use of hyperbaric oxygen as an adjunctive treatment for nonhealing wounds. Databases including PubMed, ScienceDirect, Blackwell Synergy, and The Cochrane Library were searched for relevant phrases including HBOT, HBO/HBOT, wound healing, and chronic/nonhealing wounds/ulcers.

Leg ulceration is a significant socioeconomic problem.¹ Those who suffer from leg ulcer, whatever the etiology, experience a considerable amount of pain, immobility, and a decreased quality of life. It is estimated that 1% of the Western adult population will suffer from a leg ulcer at some stage of their life.²

In their 2001 publication, McGuckin et al.³ estimated that it costs US\$3 billion each year solely to treat the symptoms of leg ulceration, not including the associated cost of approximately 2 million lost work days per annum. Leg ulcers become more common with age with the occurrence most common in the over 60s age demographic.¹

Diegelmann et al.⁴ claim that in the 15 years following their 2004 publication, the US population over age 85 will increase from 4 million to over 17 million. Hence, the treatment costs associated with ulcers are forecast to rise in the coming decades. Leg ulcers tend to persist for an extended period of time with 45% of patients in a Scottish study conducted by Cullum et al.⁵ reporting venous ulceration for longer than 10 years. Diabetic, arterial, pressure, and mixed etiology leg ulcers that do not heal often leave medical personnel with no option but to amputate the lower limb.⁶

The term “leg ulcer” is widely used to indicate venous hypertension induced ulceration; however, an ulcer may develop on the lower limbs for a number of reasons. There are four main classifications of chronic leg wounds: venous, arterial, pressure, and diabetic.⁷ Less commonly, nonhealing wounds may be the result of conditions such as vasculitis, cancer, and pyoderma gangrenosum. Table 1 summarizes the causes and treatments of the four main wound etiologies. It is important to note that a single wound may have a combination of underlying causes and

it is crucial to identify the etiology because standard treatments are recognized for each type of ulcer and inappropriate treatment based on a misdiagnosis may inadvertently impede healing and lead to wound chronicity. Recently, Chen et al.⁷ concluded that unless the underlying causes of chronic wound formation are effectively managed, chronic wounds are not going to heal.

This paper will be presented as follows. In “Biology of Wound Healing” we review the biology of wound healing including the four phases of hemostasis, inflammation, proliferation, and remodeling. We also review the role that oxygen plays in tissue repair. Following this, in “Chronic Wounds,” the chronic wound process will be discussed. We summarize the reasons presented in the literature as to why chronic wounds heal slowly or not at all. Finally, we describe hyperbaric oxygen therapy (HBOT) and the current protocols and the rationale behind the use of this treatment.

BIOLOGY OF WOUND HEALING

A successfully healing wound is typically thought to progress through four stages: hemostasis, inflammation, proliferation, and remodeling,¹⁶ although these processes are interconnected and overlapping (see Figure 1). In the sections that follow the four phases of acute wound healing will be discussed.

Hemostasis

When a tissue injury is sustained, blood from the severed capillaries streams into the wound.⁴ The immediate response of the body is aimed at impeding the blood loss.¹⁸

Table 1. Summary of the causes and treatments of different wound etiologies

Etiology	Causes	Treatments	References
Diabetic	Peripheral neuropathy Alterations in blood perfusion	Offloading by use of protective footwear, wheelchair, etc., debridement, moist wound care	Lerman and colleagues ^{6,8,9}
Venous	Venous hypertension Chronic venous insufficiency	Improve venous return/edema with compression therapy Moist wound care	Chen and colleagues ^{7,10–12}
Arterial	Arterial insufficiency	Restoration of arterial inflow with angioplasty, stents, bypasses Moist wound care (excluding unrevascularized arterial ulcers)	Enoch and colleagues ^{12–14}
Pressure (decubitus)	Unrelieved pressure leading to tissue death	Relieve pressure with dressings and pressure relieving surfaces Debridement, moist wound care	Byrne and Owen ¹⁵

The blood flow into the wound carries platelets and fibrinogen with it, both of which are important in the wound healing process.¹⁹

Fibrinogen is activated in response to the exposed epithelium to form a fibrin mesh that traps platelets. These platelets also adhere to the ruptured blood vessels, preventing further blood loss.¹⁹ Moreover, as platelets come into contact with damaged extracellular matrix (ECM) components, they release clotting factors, leading to the formation of a blood clot within the wound site.⁴ Platelets within the wound release chemical stimuli such as platelet-derived growth factor (PDGF), transforming growth factor β (TGF- β), and vascular endothelial growth factor (VEGF).^{4,20} This phase is referred to as hemostasis and, in the normal wound healing process, should last a matter of hours.

Inflammation

The onset of the next phase, inflammation, is characterized by the arrival of phagocytic neutrophils at the wound site.¹⁷ Typically, within 24 hours of injury, neutrophils have been attracted into the wound by the chemoattractants already

released and are in the process of phagocytosing foreign particles, bacteria, and the blood clot.²¹ The chemical stimulants, provided by the growth factors, also stimulate large white blood cells, monocytes, to leave neighboring blood vessels and enter the wound tissue (see Figure 2).⁴ At this stage, the cell is no longer referred to as a monocyte but rather as a macrophage.²² Macrophages are vital for the healing of a wound, because they are involved in the promotion of angiogenesis, matrix deposition, and epithelialization.²³

In the wound, as the macrophages actively migrate in response to a chemoattractant gradient, they consume the necrotic material in their path including dead neutrophils²² while releasing a variety of growth factors such as macrophage derived growth factor (MDGF), VEGF, endothelial growth factor (EGF), PDGF, and TGF- β .²⁴ The cocktail of chemicals present in the wound site attracts fibroblasts from the surrounding undamaged ECM into the wound site.⁴ The inflammation phase typically lasts for a matter of days.

Proliferation

The fibroblast is the dominant cell within the wound during the proliferative phase of healing.²⁰ Fibroblast proliferation is oxygen-dependent and the cells can only survive and perform their necessary functions in the wound where sufficient oxygen is available.²⁵ The moving band of phagocytosing macrophages typically leads the fibroblast front into the wound.²⁶

Fibroblasts, stimulated by chemoattractants such as PDGF, produce collagen, which is a major component of the ECM.¹⁷ This granulation tissue is the formation of collagenous scaffolding upon which the vascular network can extend (see Figure 2).¹⁹ Fibroblasts differentiate into myofibroblasts that align themselves along the newly formed ECM and generate tensile strength across the wound, leading to contraction.²⁷ The matrix acts as a "bed," across which endothelial cells, the cells that make up blood vessels, can migrate.²⁸ Fibroblasts continue to secrete growth factors such as VEGF, TGF- β , and PDGF.⁶ Activated to do so by the growth factors present in the wound, keratinocytes migrate and proliferate,




Figure 1. The four stages of the wound healing process, adapted from Enoch et al. with permission from BMJ Publishing Group.¹⁷




Figure 2. Schematic diagram of wound healing.

creating an epithelial layer that covers the top of the wound.¹⁹ The wound then enters the remodeling phase of healing.¹⁹

The cocktail of growth factors present in the wound stimulates the endothelial cells of vessels in the nearby healthy tissue to release proteases such as matrix metalloproteinases (MMPs).²⁹ Keratinocytes, fibroblasts, and macrophages also release MMPs.³⁰ MMPs digest the basement membrane, allowing endothelial cells to escape the confines of their parent vessel.²⁰ Growth factors such as VEGF, EGF, and TGF- β stimulate the systematic rearrangement of endothelial cells from neighboring blood vessels.⁴ The cells elongate and align to form a capillary sprout,²⁹ extending away from the original vessel (see Figure 2).³¹ This signals the start of angiogenesis, a critical process in the healing of a wound.²⁵ Angiogenesis, the formation of new blood vessels from preexisting ones, is oxygen dependent in that oxygen is needed for collagen deposition which, in turn, provides the scaffold on which blood vessels can form.²⁵ Hypoxia-inducible factor (HIF) is known to up-regulate the production of VEGF, which stimulates endothelial cell proliferation and thus aids angiogenesis during the proliferation phase.³²

Vasculogenesis, the formation of blood vessels from the differentiation of progenitor cells, also plays a part in

the formation of new blood vessels during this stage of wound healing.³³ Progenitor cells differentiate into early endothelial progenitor cells in the bone marrow and further differentiate into late endothelial progenitor cells in the vasculature system before arriving at the site of vessel formation.²⁰ Some authors have argued that a significant contribution to new blood vessel growth is made by the process of vasculogenesis (see e.g.,³⁴).

Sprout extension is facilitated by endothelial cell proliferation and further migration toward the chemical attractant.⁴ The joining of two capillary sprouts within a healing wound forms a loop through which blood can flow and new sprouts develop from this vessel thus propagating angiogenesis.²⁸ As described above, wound healing is observed to consist of the migration of a structural “wound healing unit” of macrophages, fibroblasts, ECM, and capillary sprouts through the wound site.³⁵

The extension of a blood vessel into a wound allows oxygen and other critical nutrients to be transported further into the injured region.¹⁹ This, in turn, allows the macrophage and fibroblast fronts to migrate further into the wound, and thus the healing unit progresses into the injured tissue.²⁸ When the unit has completely swept through the wound site, blood vessels are networked over the entire space, oxygen levels are returned to normal and the healing process stops.⁴

Remodeling

The remodeling phase can last for several months or even years.¹⁹ During the remodeling stage, the absence of hypoxia results in a marked decline in the vascular density and increased cellular apoptosis.³⁶ Also during this phase, the collagen matrix is remodeled, complete wound contraction occurs, and wound strength is increased from about 20% normal tensile strength 3 weeks post injury to 80% within a timeframe of 2 years.³⁷

The importance of oxygen in wound healing

As already discussed, oxygen is a critical nutrient required for successful healing of a wound and this notion is well documented in the literature.^{24,28,35,38–48} Oxygen plays an important role in each stage of the wound healing process. According to Tompach et al.,³⁵ in the inflammatory stage, oxygen controls the migration and proliferation of fibroblasts. Bacteria are kept under control in acute wounds by intracellular oxidative mechanisms of leukocytes and molecular oxygen must be present for the production of the required oxidants.⁴⁹ For successful healing to occur, infection must be prevented and resistance to infection depends on oxygen content within the wound as neutrophils become ineffective under hypoxic conditions.⁵⁰

In the proliferative phase, angiogenesis requires oxygen.²⁵ In the remodeling stage, the production of collagen by fibroblasts is well-documented as being dependent on oxygen.²¹ There are several steps in collagen synthesis that require oxygen. For example, the enzymes responsible for converting proline to hydroxyproline, allowing procollagen peptides to achieve their triple helix form, require molecular oxygen.²⁵

Conversely, it is widely thought that the absence of oxygen from the central space of the wound initially

stimulates the healing process.^{13,25,35,46,51} This wound hypoxia (a deficiency of oxygen) must be corrected in order to provide sufficient oxygen to support tissue repair.²⁵ It is thought that correction of the oxygen level throughout the entire wound may arrest the healing process due to the failure of macrophages to produce growth factors such as VEGF.^{38,52} Lack of oxygen within a wound stimulates the healing mechanism but will frustrate the overall process if hypoxia persists.⁵³ Furthermore, the macrophage production of the chemical stimulus, VEGF, has been shown to be up-regulated by both hypoxic and hyperoxic conditions.^{19,54} It is clear that a delicate relationship exists between the healing of a wound and the oxygen level within the wound site.¹³

Other important factors in wound healing

There are many other intrinsic factors, besides molecular oxygen, which are thought to affect the healing of wounds including oxidants species, lactate, and HIF. During the phagocytosis of debris in the inflammation stage of wound healing, phagocytic cells such as macrophages and neutrophils consume increased amounts of oxygen.⁵⁵ This is commonly referred to as the “oxidative burst” and the consumption leads to the conversion of oxygen to oxidation species such as superoxide and hydrogen peroxide.⁵⁶ These oxidants may assist wound healing by up regulating fibroblast migration and proliferation.⁵⁷ Lactate is produced by fibroblasts and is a by-product of the oxidative burst. VEGF and collagen production are elicited by lactate.⁵⁸ Interestingly, lactate levels are similar in both low and high levels of oxygen.⁵⁹ In fact, Trabold et al. propose that “lactate induces a biochemical perception of hypoxia and instigates several signals that activate growth factor signals while the continued presence of oxygen allows endothelial cells and fibroblasts to reproduce and deposit collagen.”⁵⁵ Finally, expression of HIF by endothelial cells is simulated during times of hypoxia. This HIF then binds to DNA that regulates the expression of VEGF.⁴

Extrinsic factors that affect wound healing are numerous and include medication, stress, depression, nutrition, and age. Many medications are known to affect wound repair. For example, steroids are thought to down-regulate growth factors and collagen deposition,⁶⁰ aspirin suppresses inflammation, and chemotherapeutic drugs arrest cell replication.⁶¹ Stress has been shown to delay the healing of punch biopsies and may be caused by changes in the secretion of proinflammatory cytokines during times of stress.⁶² Similarly, depression has been linked to a decrease in cellular immunity and may delay wound repair.⁶³ Wounding can alter nutritional requirements and it is therefore crucial that patients at risk of malnutrition change their diet accordingly as failure to do so can adversely affect the healing process.⁶⁴ The wound healing process is often delayed in aged individuals due to a decrease in cell proliferation, collagen synthesis, and angiogenesis.⁶⁵ As Smith et al.⁶⁶ concluded, it is likely that supplementing oxygen to wounds that fail to heal due to reasons besides hypoxia, such as those mentioned above, will have little benefit.

Mathematical models of wound healing

Mathematical modeling can provide independent insight into a biological process and has the potential to generate theoretical predictions that could not have been anticipated in advance, thereby stimulating further biomedical research and reducing the need for time-consuming, technically difficult, and often costly experiments.²³ As such, many would argue that mathematical models must form a crucial part of research into any biological process, including the healing of wounds.⁶⁷ Mathematical modeling gives the wound healing researcher an insight into the mechanisms and relative importance of processes, information that is also useful in the treatment methodologies to be implemented by medical staff.⁶⁸ The development of mathematical models that describe the numerous components of the wound healing process, together with their synergistic or antagonistic interactions, will provide the means to identify which elements of the wound healing process may be manipulated in a rational, mechanism-based strategy for improved clinical management of wound repair.

CHRONIC WOUNDS

A chronic wound is one in which healing fails to proceed through an orderly and timely process to produce anatomic and functional integrity, or proceed through the repair process without establishing a sustained anatomic and functional result.⁶⁹ These wounds are often a surface manifestation of an underlying disease such as venous insufficiency, arterial disease, or diabetes.²¹ Treatment tends to focus on treating the surface ulcer and commonly ends in nothing more than added expense without successful healing.⁷⁰

The chronic wound healing process

The factors involved in the development of a chronic wound remain unclear;^{6,71} however, the most common cause, according to Mathieu et al.²¹ is thought to be related to the detrimental effects of prolonged wound hypoxia (oxygen deficiency). It has been suggested that while oxidant species, produced by neutrophils and macrophages within the wound, may serve as messengers to promote healing, overproduction may in fact overwhelm the immune system and delay healing.⁵⁶ Chronic wounds can be arrested in any one of the stages of wound healing,⁴ but disruption commonly occurs in the inflammatory or proliferative phases.¹⁷ Braiman-Wiksman argue that within the proliferative phase, reepithelialization is crucial for successful healing.⁷²

There is growing consensus that a chronic wound remains “stuck” in the inflammatory stage of healing with an overabundant production of neutrophils.^{73,74} Diegelmann et al.⁴ state that this excessive production can have a detrimental effect on healing by destroying growth factors (and thus reducing the chemotactic and proliferative stimulus that these chemicals provide) through neutrophil production of proteolytic enzymes and degrading ECM components.⁷³ In chronic wounds, insufficient ECM is deposited (which is likely due to fibroblast production and remodeling of collagen being dependent on a sufficient

supply of oxygen), leading to a weakened tissue that can easily rupture.⁴ Others have reported high levels of MMPs, which can lead to excessive ECM degradation.^{8,75} Furthermore, blocked or defective cell proliferation may prevent healing.^{20,76}

Numerous mathematical models of chronic wound healing have been developed. For example, Pettet et al.⁷⁷ were able to simulate wound chronicity by assuming that capillary budding is down-regulated in chronic wounds. Byrne et al.²⁸ simulated a nonhealing wound by assuming that endothelial cell proliferation and chemoattractant production rates are reduced in chronic wounds.

Treatment of chronic wounds

Chronic wounds are resistant to treatment and healing progresses very slowly or not at all.¹³ Traditional approaches to treating leg ulcers have involved debridement, pressure management, antibiotic treatment, compression therapy, and the use of specialized wound dressings.⁷⁸ Some more recent approaches to treating foot ulcers include the application of cultured skin substitutes (Apligraf and Dermagraft), electrical stimulation, HBOT, and vacuum assisted closure.^{51,79–82} The use of HBOT to treat certain chronic wounds will be discussed in the following section.

HBOT

HBOT is the intermittent exposure of the body to 100% oxygen at a pressure > 1 atmosphere absolute (ATA).⁴⁴ HBOT has been demonstrated to reduce the rate of major lower limb amputations among diabetics.^{51,83–86} The analysis by Fife et al.⁸⁷ showed that the economic and emotional cost of amputation undoubtedly exceeds the cost of successful treatment with HBOT. HBOT is administered either in a multiplace chamber where the air within the chamber is pressurized and each patient receives 100% oxygen through a gas mask or a monoplace chamber where the sole patient is entirely surrounded by pressurized oxygen.⁴⁴

HBOT can only be delivered to a patient systemically.³⁹ Confusion sometimes exists with the use of the term, “topical HBO” used to describe the application of 100% oxygen to the surface of the wound at 1 ATA. This is typically done by injecting oxygen into a plastic bag encasing the lower limb. As it is physiologically impossible to apply pressure to specific body parts such as the lower leg, at pressures much above ambient without creating a tourniquet effect, the use of this modality should more accurately be referred to as “topical oxygen therapy” or TOT for short. Gordillo et al.²⁵ argue that this therapy is unlikely to result in deep perfusion of oxygen through the skin and wound surface, making the topical approach less than optimal.

Other research has shown a very limited depth of penetration for topical oxygen perhaps as shallow as 50–100 μm .⁸⁸ Advocates of this technique for wound healing point out certain advantages, such as lower costs, greater portability, and reduced risks of oxygen toxicity when compared with conventional HBOT⁵⁶ and, although the technique seems to hold theoretical promise, the only randomized-controlled trial done to date showed no

difference in healing rates between topical oxygen therapy and conventional treatment.⁸⁹

There are currently 13 indications for which the Undersea and Hyperbaric Medical Society (UHMS) recommend treatment with HBOT.⁹⁰ Wound related indications include delayed radiation injury (osteoradionecrosis), necrotizing soft tissue infections, enhancement of healing in selected problem wounds, thermal burns, compromised skin grafts and flaps, crush injury, clostridial myositis, myonecrosis (gas gangrene), and refractory osteomyelitis. Nonwound related indications include decompression sickness, air/gas embolism, carbon monoxide poisoning, exceptional blood loss anemia, and intracranial abscess. Babul et al.⁴¹ state that HBOT may also serve to improve the short and long-term prognosis of sports-related injuries; however, this is currently not a UHMS-recognized condition for treatment with HBOT as evidence is lacking.

Side effects of HBOT

Although HBOT is generally regarded as a safe treatment, there are several potential side effects. The most common side effect is ear and sinus barotrauma, which occur in approximately 52 of every 10,000 cases.¹⁹ Another side effect of HBOT is myopia, which can last several weeks after treatment has stopped.⁹¹ HBOT is associated with an oxygen toxicity-induced convulsion rate of about 1 in 10,000.¹⁹ It should be noted that these convulsions are not life threatening. To prevent oxygen toxicity, it is recommended that HBOT protocols involving 2.4 ATA allow for 5 minutes of air breathing in the chamber every 30 minutes.⁴⁵ The incidence of decompression sickness in multiplace chamber attendants is also estimated to be 1 in 10,000.¹⁹

Fires within chambers occur at a rate of about one per year worldwide.⁹² Fire hazard is the most common fatal complication, yet hospital fires, in general, are far more common.^{45,92} Some patients with severe congestive heart failure experience a decline in cardiac function as a result of receiving HBOT.⁹³ To safeguard against this, patients with lower than 35% cardiac ejection are typically not treated with HBOT. To minimize the chance of side effects, patients should be thoroughly screened and monitored during their treatment by trained hyperbaric physicians and nurses.

The HBOT protocol

There is much debate about the optimal HBOT protocol in treating chronic wounds.^{35,94–96} Quantity and quality of evidence varies by etiology, stage, and chronicity of the wound; evidence is best for efficacy in osteoradionecrosis and ischemic diabetic ulcers. Although HBOT is typically used as an adjunctive therapy for treating chronic wounds, many clinicians lack a full knowledge of the evidence-based data that support its use.⁹⁷ Mason et al.⁷⁸ concluded that the role of HBOT in wound care could neither be ruled in nor out based on the available information and evidence at the time. There are also several authors who conclude that there is sufficient evidence to support the use of HBOT as an adjunctive treatment for nonhealing wounds.^{39,51,83,98,99} In 1999, the American Diabetes Association endorsed the use of HBOT in severe diabetic

wounds that fail to respond to more traditional approaches.¹⁰⁰ The Centers for Medicare and Medicaid Services stated in 2002 that there was adequate evidence to conclude that HBOT is clinically effective, reasonable and necessary in the treatment of certain (Wagner grade III or higher and recalcitrant to 30 days of appropriate wound treatment) diabetic lower limb-threatening wounds.¹⁰¹ In 2003, the UHMS committee reported that the available evidence supports the use of adjunctive HBOT for diabetic foot ulcers.⁹⁰ More recently, in 2006, guidelines for the treatment of arterial insufficiency ulcers and diabetic ulcers, established by request of the Wound Healing Society, supported the use of adjunct HBOT for ischemic, diabetic wounds, and recommended further investigation for ischemic, nondiabetic ulcers.^{102,9} It should be noted that the evidence supporting the use of HBOT for chronic wounds is limited mainly to diabetic wounds.^{51,71,84,85,91,92,100,103}

Whether HBOT is effective or not, there is the question as to whether or not HBOT is cost effective. In their reports to the Australian Federal Government, the Medical Services Advisory Committee (MSAC) stated that although there is evidence of HBOT's effectiveness in treating diabetic wounds, there is inadequate proof to show that the use of HBOT is cost-effective.⁸⁶ Leach et al.⁴⁵ state that more work is needed to establish timing, indications and regimens to achieve the best clinical and cost-effective results.

Even among those that advocate the use of HBOT in wound healing, the HBOT protocol varies significantly. There is still much uncertainty surrounding the choice of a regimen that will obtain the optimal therapeutic affect of pressure, duration of treatment, and number of repeat sessions of HBOT for the healing of chronic wounds.^{35,40,104,105} Moreover, there is insufficient evidence to ascertain at which stage of the healing process to start the treatment.⁹⁹

Some authors think that the stimulation of angiogenesis is one of the most important features of HBOT in the treatment of chronic wounds. Figure 3 shows the calculated values of the mean angiogenesis score by Hopf et al.⁵³ with changes in the percentage oxygen inspired and the atmospheric pressure applied to wounded mice. The angiogenesis grading was stepwise with 0 indicating no vessels,




Figure 3. Bar graph of the mean angiogenesis score at various pressure and oxygen levels from Hopf et al.⁵³ Reprinted with permission from Blackwell Publishing.

0.5 scattered vessels, and 1 maximal vessels. The mean angiogenesis score is then calculated by averaging over the entire sample. We see that the mean angiogenesis score increases as the oxygen level changes from that in room air to pure oxygen. The score increases with increasing pressure until 2.5 ATA, when it begins to decline. Oxygen was delivered to the mice in an enclosed chamber for 90 minutes twice a day for 7 days. Hopf et al.⁵³ concluded that angiogenesis was significantly greater in all hyperoxic groups compared with room air-exposed controls.

Mathematical models allow us to investigate the optimal HBOT protocol. By simulating the healing of a chronic wound under treatment by various durations and frequencies of HBOT sessions, one may be able to determine, from a theoretical viewpoint, the optimal procedure for administering HBOT. This can be achieved without costly laboratory experiments or clinical trials.

The rationale behind HBOT

The primary rationale behind the use of HBOT in the treatment of chronic wounds is to correct the amount of oxygen delivered to the wound site.¹⁰⁵ This is achieved by the HBOT-induced increase in the blood-oxygen level within the injury and the reallocation of blood flow to hypoxic areas due to hyperoxic vasoconstriction in the surrounding normal tissue.²¹

There are two methods by which oxygen reaches the wounded tissue. The first is attachment to hemoglobin molecules and the second as dissolved oxygen in the plasma. According to Kessler et al.,⁵¹ HBOT cannot significantly increase the amount of oxygen bound to hemoglobin molecules but can increase the amount of oxygen dissolved in the plasma. A person breathing room air already can have at any one time up to 97% of their hemoglobin molecules bound to oxygen so that increases in the oxygen level and pressure will not significantly increase the oxygen content delivered via hemoglobin.¹⁹ Furthermore, even if HBOT did significantly increase the amount of oxyhemoglobin present in the vasculature, the lack of blood vessels in the wound would prevent oxygen reaching the innermost parts of the injury, where hypoxia is greatest and the oxygen is needed the most.⁴⁸ On the other hand, even poorly perfused wounds can receive oxygen via hyperoxygenated plasma.¹⁹

Table 2 shows theoretical arterial oxygen tensions and the amount of oxygen dissolved in the blood for various HBOT protocols. These figures are calculated using ideal oxygen pressure laws (see e.g.,^{19,88}) and an oxygen

Table 2. Theoretical arterial oxygen tension and oxygen blood content for different treatment protocols

Oxygen % level	Arterial oxygen tension (mmHg)	Milliliters of oxygen in plasma per dL of blood
21	100	0.31
100	660	2.0
100	1400	4.3
100	2200	6.8

ATA, atmosphere absolute.

solubility in blood of 0.0031 mL/dL of blood per mmHg of arterial oxygen tension. A healthy adult has been reported to require about 6 mL of oxygen/dL of blood and hence the data in Table 2 suggest that HBOT can provide sufficient oxygen in the plasma to support the body's requirements.

The positive effects of HBOT stem from the benefit of increasing the tissue oxygen tension and/or pressure within the wound site and include¹⁹:

1. Alteration of ischemic effect.
2. Reduction of edema.
3. Modulation of the production of nitric oxide.
4. Modification of the effect of growth factors and cytokines.
5. Promotion of cellular proliferation.
6. Acceleration of collagen deposition.
7. Stimulation of capillary budding.
8. Accelerated microbial oxidative killing.
9. Interference with bacterial proliferation.
10. Modulation of the immune system response.
11. Enhancement of oxygen radical scavengers, thereby reducing ischemia reperfusion injury.

Therapeutic effects such as increased collagen synthesis, improved bacterial killing, and antibiotic potentiation have been reported to occur during the periods of elevated oxygen tension, while other effects including suppression of bacterial propagation, down-regulation of inflammatory signals, and prevention of leukocyte activation and adhesion following ischemic reperfusion may continue even once the treatment has ceased.⁹⁰

DISCUSSION

It is clear that more reliable clinical data are needed in order for HBOT to be recognized as an appropriate adjunct treatment for certain nonhealing wounds. In order to fully understand the chronic wound and, more importantly, to identify exactly what prevents these wounds from healing, time-consuming, technically difficult and costly experiments, such as in vitro and animal studies, need to be performed. Alternatively, a validated mathematical model may provide independent insight into the wound healing process and has the potential to generate theoretical predictions which could not have been anticipated in advance.²³

This paper has reviewed the chronic wound process, the possible reasons as to why chronic wounds heal slowly and the use of adjunct HBOT to accelerate the healing rate of chronic wounds. As theoreticians, experimentalists, and clinicians work together, perhaps we can establish the role for HBOT in the treatment of chronic wounds.

ACKNOWLEDGMENTS

The authors would like to acknowledge the very helpful comments of the anonymous referees. This work was supported by the award of a doctoral scholarship from the Institute of Health and Biomedical Innovation at Queensland University of Technology (J.T.).

REFERENCES

1. Kucharzewski M, Slezak A, Franek A. Topical treatment of non-healing venous leg ulcers by cellulose membrane. *Phlebologie* 2003; 32: 147–51.
2. Nelson EA, Bradley MD. Dressings and topical agents for arterial leg ulcers. Cochrane Database of Systematic Reviews, 2007, issue 1. CD001836. DOI: 10.1002/14651858.CD001836.pub2.
3. McGuckin M, Waterman R, Brooks J, Cherry G, Porten L, Hurley S, Kerstein MD. Validation of venous leg ulcer guidelines in the United States and United Kingdom. *Am J Surg* 2002; 183: 132–7.
4. Diegelmann RF, Evans MC. Wound healing: an overview of acute, fibrotic and delayed healing. *Front Biosci* 2004; 9: 283–9.
5. Cullum N, Nelson EA, Fletcher AW, Sheldon TA. Compression for venous leg ulcers. Cochrane Database of Systematic Reviews, 2001, issue 2. CD000265. DOI: 10.1002/14651858.CD000265.
6. Lerman OZ, Galiano RD, Armour M, Levine JP, Gurtner GC. Cellular dysfunction in the diabetic fibroblast. *Am J Pathol* 2003; 162: 303–12.
7. Chen WYJ, Rogers AA. Recent insights into the causes of chronic leg ulceration in venous diseases and implications on other types of chronic wounds. *Wound Rep Reg* 2007; 15: 434–49.
8. Darby IA, Bisucci T, Hewitson TD, MacLellan DG. Apoptosis is increased in a model of diabetes-impaired wound healing in genetically diabetic mice. *Int J Biochem Cell Biol* 1997; 29: 191–200.
9. Steed DL, Attinger C, Colaizzi T, Crossland M, Franz M, Harkless L, Johnson A, Moosa H, Robson M, Serena T, Sheehan P, Veves A, Wiersma-Bryant L. Guidelines for the treatment of diabetic ulcers. *Wound Rep Reg* 2006; 14: 680–92.
10. Brown NJ, Smyth EAE, Cross SS, Reed MWR. Angiogenesis induction and regression in human surgical wounds. *Wound Rep Reg* 2002; 10: 245–51.
11. Trent JT, Falabella A, Eaglstein WH, Kirsner RS. Venous ulcers: pathophysiology and treatment options. *Ostomy Wound Manage* 2005; 51: 38–54.
12. Grey JE, Harding KG, Enoch S. Venous and arterial leg ulcers. *BMJ* 2006; 332: 347–50.
13. Roeckl-Wiedmann I, Bennett M, Kranke P. Systematic review of hyperbaric oxygen in the management of chronic wounds. *Br J Surg* 2005; 92: 24–32.
14. Bauer SM, Goldstein LJ, Bauer RJ, Chen H, Putt M, Velazquez OC. The bone marrow-derived endothelial progenitor cell response is impaired in delayed wound healing from ischemia. *J Vasc Surg* 2006; 43: 134–41.
15. Grey JE, Harding KG, Enoch S. Pressure ulcers. *BMJ* 2006; 332: 472–5.
16. Ayello EA, Cuddigan JE. Conquer chronic wounds with wound bed preparation. *Nurse Pract* 2004; 29: 8–25.
17. Enoch S, Grey JE, Harding KG. Recent advances and emerging treatments. *BMJ* 2006; 332: 962–5.
18. Molnar JA. Overview of nutrition and wound healing. In: Molnar JA, editor. *Nutrition and wound healing*. Boca Raton, FL: CRC Press, 2006: 1–14.
19. Sheffield PJ, Smith APS. Physiological and pharmacological basis of hyperbaric oxygen therapy. In: Bakker DJ, Cramer FS, editors. *Hyperbaric surgery*. Flagstaff, AZ: Best Publishing Company, 2002: 63–109.

20. Bauer SM, Bauer RJ, Velazquez OC. Angiogenesis, vasculogenesis, and induction of healing in chronic wounds. *Vasc Endovasc Surg* 2005; 39: 293–306.
21. Mathieu D. Hyperbaric oxygen therapy in the management of non-healing wounds. In: Bakker DJ, Cramer FS, editors. *Hyperbaric surgery*. Flagstaff, AZ: Best Publishing Company, 2002: 317–39.
22. Bellingan GJ, Caldwell H, Howie SEM, Dransfield I, Haslett C. In vivo fate of the inflammatory macrophage during the resolution of inflammation. *J Immunol* 1996; 157: 2577–85.
23. Byrne HM, Owen MR. Use of mathematical models to simulate and predict macrophage activity in diseased tissue. In: Burke B, Lewis CE, editors. *The macrophage*. 2nd ed. Oxford, UK: Oxford University Press, 2002: 1–59.
24. Tandara AA, Mustoe TA. Oxygen in wound healing—more than a nutrient. *World J Surg* 2004; 28: 294–300.
25. Gordillo GM, Sen CK. Revisiting the essential role of oxygen in wound healing. *Am J Surg* 2003; 186: 259–63.
26. Gaffney EA, Pugh K, Maini PK, Arnold F. Investigating a simple model of cutaneous wound healing angiogenesis. *J Math Biol* 2002; 45: 337–74.
27. Bauer SM, Bauer RJ, Liu ZJ, Chen H, Goldstein L, Velazquez OC. Vascular endothelial growth factor-C promotes vasculogenesis, angiogenesis, and collagen constriction in three-dimensional collagen gels. *J Vasc Surg* 2005; 41: 699–707.
28. Byrne HM, Chaplain MAJ, Evans DL, Hopkinson I. Mathematical modelling of angiogenesis in wound healing: comparison of theory and experiment. *J Theoretical Med* 2000; 2: 175–97.
29. Mantzaris NV, Webb S, Othmer HG. Mathematical modeling of tumor-induced angiogenesis. *J Math Biol* 2004; 49: 111–87.
30. Trengove NJ, Stacey MC, MacAuley S, Bennett N, Gibson J, Burslem F, Murphy G, Schultz G. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. *Wound Rep Reg* 1999; 7: 442–52.
31. Pettet GJ, Chaplain MAJ, McElwain DLS, Byrne HM. On the role of angiogenesis in wound healing. *Proc R Soc Lond B* 1996; 263: 1487–93.
32. Yamakawa M, Liu LX, Date T, Belanger AJ, Vincent KA, Akita GY, Kuriyama T, Cheng SH, Gregory RJ, Jiang C. Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. *Circ Res* 2003; 93: 664–73.
33. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. *Circ Res* 1999; 85: 221–8.
34. Tepper OM, Capla JM, Galiano RD, Ceradini DJ, Callaghan MJ, Kleinman ME, Gurtner GC. Adult vasculogenesis occurs through in situ recruitment, proliferation, and tubulization of circulating bone marrow-derived cells. *Blood* 2005; 105: 1068–77.
35. Tompach PC, Lew D, Stoll JL. Cell response to hyperbaric oxygen treatment. *Int J Oral Maxillofac Surg* 1997; 26: 82–6.
36. Lokmic Z, Darby IA, Thompson EW, Mitchell GM. Time course analysis of hypoxia, granulation tissue and blood vessel growth, and remodeling in healing rat cutaneous incisional primary intention wounds. *Wound Rep Reg* 2006; 14: 277–88.
37. Natarajan S, Williamson D, Stiltz AJ, Harding K. Advances in wound care and healing technology. *Am J Clin Dermatol* 2000; 1: 269–75.
38. Knighton DR, Hunt TK, Scheuenstuhl H, Halliday BJ, Werb Z, Banda MJ. Oxygen tension regulates the expression of angiogenesis factor by macrophages. *Science* 1983; 221: 1283–5.
39. Gajendrareddy PK, Sen CK, Horan MP, Marucha PT. Hyperbaric oxygen therapy ameliorates stress-impaired dermal wound healing. *Brain Behav Immun* 2005; 19: 217–22.
40. Kalliainen LK, Gordillo GM, Schlanger R, Sen CK. Topical oxygen as an adjunct to wound healing: a clinical case series. *Pathophysiol* 2003; 9: 81–7.
41. Babul S, Rhodes EC. The role of hyperbaric oxygen therapy in sports medicine. *Sports Med* 2000; 30: 395–403.
42. Malda J, van Blitterswijk CA, van Geffen M, Martens DE, Tramper J, Riesle J. Low oxygen tension stimulates the redifferentiation of dedifferentiated adult human nasal chondrocytes. *Osteoarthritis Cartilage* 2004; 12: 306–13.
43. Dimitrijevic SD, Paranjape S, Wilson JR, Gracy RW, Mills JG. Effect of hyperbaric oxygen on human skin cells in culture and in human dermal and skin equivalents. *Wound Rep Reg* 1999; 7: 53–64.
44. Gill AL, Bell CNA. Hyperbaric oxygen: its uses, mechanisms of action and outcomes. *Q J Med* 2004; 97: 385–95.
45. Leach RM, Rees PJ, Wilmshurst P. ABC of oxygen: hyperbaric oxygen therapy. *BMJ* 1998; 317: 1140–43.
46. Siddiqui A, Davidson JD, Mustoe TA. Ischemic tissue oxygen capacitance after hyperbaric oxygen therapy: a new physiologic concept. *Plast Reconstr Surg* 1997; 99: 148–54.
47. Hollander DA, Hakimi MY, Hartmann A, Wilhelm K, Windolf J. The influence of hyperbaric oxygenation (HBO) on proliferation and differentiation of human keratinocyte cultures in vitro. *Cell Tissue Banking* 2000; 1: 261–9.
48. Hunt TK, Gimbel ML. Hyperbaric oxygen and wound healing. In: Bakker DJ, Cramer FS, editors. *Hyperbaric surgery*. Flagstaff, AZ: Best Publishing Company, 2002: 439–59.
49. Gottrup F. Oxygen in wound healing and infection. *World J Surg* 2004; 28: 312–5.
50. Greif R, Akca O, Horn E, Kurz A, Sessler DI. Supplemental perioperative oxygen to reduce the incidence of surgical-wound infection. *N Engl J Med* 2000; 342: 161–7.
51. Kessler L, Bilbault P, Ortega F, Grasso C, Passemard R, Stephan D, et al. Hyperbaric oxygenation accelerates the healing rate of nonischemic chronic diabetic foot ulcers. *Diabetes Care* 2003; 26: 2378–82.
52. Knighton DR, Silver IA, Hunt TK. Regulation of wound-healing angiogenesis - effect of oxygen gradients and inspired oxygen concentration. *Surgery* 1981; 90: 262–70.
53. Hopf HW, Gibson JJ, Angeles AP, Constant JS, Feng JJ, Rollins MD, et al. Hyperoxia and angiogenesis. *Wound Rep Reg* 2005; 13: 558–64.
54. Al-Waili NS, Butler GJ. Effects of hyperbaric oxygen on inflammatory response to wound and trauma: possible mechanism of action. *Sci World J* 2006; 6: 425–41.
55. Trabold O, Wagner S, Wicke C, Scheuenstuhl H, Hussain MZ, Rosen N, et al. Lactate and oxygen constitute a fundamental regulatory mechanism in wound healing. *Wound Repair Reg* 2003; 11: 504–9.
56. Sen CK, Khanna S, Gordillo G, Bagchi D, Bagchi M, Roy S. Oxygen, oxidants, and antioxidants in wound healing: an emerging paradigm. *Ann New York Acad Sci* 2002; 957: 239–49.

57. Yahagi N, Kono M, Kitahara M, Ohmura A, Sumita O, Hashimoto T, Hori K, Ning-Juan C, Woodson P, Kubota S, Murakami A, Takamoto S. Effect of electrolyzed water on wound healing. *Artif Organs* 2000; 24: 984–7.
58. Dalton SJ, Whiting CV, Bailey JR, Mitchell DC, Tarlton JF. Mechanisms of chronic skin ulceration linking lactate, transforming growth factor- β , vascular endothelial growth factor, collagen remodeling, collagen stability, and defective angiogenesis. *J Invest Dermatol* 2007; 127: 958–68.
59. Hunt TK, Conolly WB, Aronson SB, Goldstein P. Anaerobic metabolism and wound healing: an hypothesis for the initiation and cessation of collagen synthesis in wounds. *Am J Surg* 1978; 135: 328–32.
60. Wicke C, Halliday B, Allen D, Roche NS, Scheuenstuhl H, Spencer MM, Roberts AB, Hunt TK. Effects of steroids and retinoids on wound healing. *Arch Surg* 2000; 135: 1265–70.
61. Hunt TK. Disorders of wound healing. *World J Surg* 1980; 4: 271–7.
62. Cole-King A, Harding KG. Psychological factors and delayed healing in chronic wounds. *Am Psychosom Med* 2001; 63: 216–20.
63. Herbert TB, Cohen S. Depression and immunity: a meta-analytic review. *Psychol Bull* 1993; 113: 472–86.
64. Casey G. The importance of nutrition in wound healing. *Nurs Stand* 1998; 13: 51–6.
65. Gosain A, DiPietro LA. Aging and wound healing. *World J Surg* 2004; 28: 321–6.
66. Smith BM, Desvigne LD, Slade JB, Dooley JW, Warren DC. Transcutaneous oxygen measurements predict healing of leg wounds with hyperbaric therapy. *Wound Repair Reg* 1996; 4: 224–9.
67. Cook J. Mathematical models for dermal wound healing: wound contraction and scar formation. PhD Thesis, University of Washington, 1995.
68. McDougall S, Dallon J, Sherratt J, Maini P. Fibroblast migration and collagen deposition during dermal wound healing: mathematical modelling and clinical implications. *Phil Trans R Soc A* 2006; 364: 1385–405.
69. Lazarus GS, Cooper DM, Knighton DR, Margolis DJ, Pecoraro RE, Rodeheaver G, Robson MC. Definitions and guidelines for assessment of wounds and evaluation of healing. *Arch Dermatol* 1994; 130: 489–93.
70. Ramstadius B. Leg ulcer management. *Aust Nurs J* 1997; 5: 22.
71. Anonymous. Consensus development conference on diabetic foot wound care. *Diabetes Care* 1999; 22: 1354–60.
72. Braiman-Wiksmann L, Solomonik I, Spira R, Tennenbaum T. Novel insights into wound healing sequence of events. *Toxicol Pathol* 2007; 35: 767–79.
73. Agren MS, Eaglstein WH, Ferguson MW, Harding KG, Moore K, Saarialho-Kere UK, Schultz GS. Causes and effects of the chronic inflammation in venous leg ulcers. *Acta Derm Venereol* 2000; 210: 3–17.
74. Yager DR, Zhang LY, Liang HX, Diegelmann, IK, Cohen, RF. Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids. *J Invest Dermatol* 1996; 107: 743–8.
75. Wysocki AB, Kusakabe AO, Chang S, Tuan T. Temporal expression of urokinase plasminogen activator, plasminogen activator inhibitor and gelatinase-B in chronic wound fluid switches from a chronic to acute wound profile with progression to healing. *Wound Repair Reg* 1999; 7: 154–65.
76. Moore K, Ruge F, Harding KG. T lymphocytes and the lack of activated macrophages in wound margin biopsies from chronic leg ulcers. *Br J Dermatol* 1997; 137: 188–94.
77. Pettet GJ, Byrne HM, McElwain DLS, Norbury J. A model of wound-healing angiogenesis in soft tissue. *Mathemat Biosci* 1996; 136: 35–63.
78. Mason J, O'Keefet C, Hutchinson A, McIntosh A, Young R, Booth A. A systematic review of foot ulcer in patients with type 2 diabetes mellitus. II: treatment. *Diabetic Med* 1999; 16: 889–909.
79. Eginton MT, Brown KR, Seabrook GR, Towne JB, Cambria RA. A prospective randomized evaluation of negative-pressure wound dressings for diabetic foot wounds. *Ann Vasc Surg* 2003; 17: 645–9.
80. Curran MP, Plosker GL. Bilayered bioengineered skin substitute (Apligraf): a review of its use in the treatment of venous leg ulcers and diabetic foot ulcers. *Biodrugs* 2002; 16: 439–55.
81. Cukjati D, Reberšek S, Miklavcic D. A reliable method of determining wound healing rate. *Med Biol Eng Comput* 2001; 39: 263–71.
82. Wood Z. Hyperbaric oxygen in the management of chronic wounds. *Br J Nurs* 2002; 11: S16–24.
83. Broussard CL. Hyperbaric oxygenation and wound healing. *J Vasc Nurs* 2004; 22: 42–8.
84. Faglia E, Favales F, Aldeghi A, Calia P, Quarantiello A, Oriani G, Michael M, Campagnoli P, Morabito A. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcers. *Diabetes Care* 1996; 19: 1338–43.
85. Kalani M, Jörneskog G, Naderi N, Lind F, Brismar K. Hyperbaric oxygen (HBO) therapy in treatment of diabetic foot ulcers long-term follow-up. *J Diabetes Complications* 2002; 16: 153–8.
86. Hyperbaric oxygen therapy. Medical Services Advisory Committee Applications 1018-1020; November 2000.
87. Fife CE, Buyukcakar C, Otto GH, Sheffield PJ, Warriner RA, Love TL, Mader J. The predictive value of transcutaneous oxygen tension measurement in diabetic lower extremity ulcers treated with hyperbaric oxygen therapy: a retrospective analysis of 1144 patients. *Wound Rep Reg* 2002; 10: 198–207.
88. Piantadosi CA. Physiology of hyperbaric hyperoxia. *Respir Care Clin N Am* 1999; 5: 7–19.
89. Leslie CA, Sapico FL, Ginunas VJ, Adkins RH. Randomized controlled trial of topical hyperbaric oxygen for treatment of diabetic foot ulcers. *Diabetes Care* 1988; 11: 111–5.
90. Warriner III RA, Hopf HW. Enhancement of healing in selected problem wounds. In: Feldmeier JJ, editor. *The hyperbaric oxygen committee report*. Kensington, MD: Undersea and Hyperbaric Medical Society, 2003: 41–55.
91. Heyneman CA, Lawless-Liday C. Using hyperbaric oxygen to treat diabetic foot ulcers: safety and effectiveness. *Critical Care Nurse* 2002; 22: 52–60.
92. Williams RL. Hyperbaric oxygen therapy and the diabetic foot. *J Am Podiatr Med Assoc* 1997; 87: 279–92.
93. Wright J. Hyperbaric oxygen therapy for wound healing, 2001, World Wide Wounds. Available at: <http://www.worldwidewounds.com>.
94. Thom SR, Bhopale VM, Velazquez OC, Goldstein LJ, Thom LH, Buerk DG. Stem cell mobilization by hyperbaric oxygen. *Am J Physiol Heart Circ Physiol* 2006; 290: 1378–86.

95. Günther A, Manaenko A, Franke H, Dickel T, Berrouschot J, Wagner A, Illes P, Reinhardt R. Early biochemical and histological changes during hyperbaric or normobaric reoxygenation after in vitro ischaemia in primary corticoencephalic cell cultures of rats. *Brain Res* 2002; 946: 130–8.
96. Niklas A, Brock D, Schober R, Schulz A, Schneider D. Continuous measurements of cerebral tissue oxygen pressure during hyperbaric oxygenation – HBO effects on brain edema and necrosis after severe brain trauma in rabbits. *J Neurol Sci* 2004; 219: 77–82.
97. Wunderlich RP, Peters EJG, Lavery LA. Systemic hyperbaric oxygen therapy: lower-extremity wound healing and the diabetic foot. *Diabetes Care* 2000; 23: 1551–5.
98. Chen S, Yu C, Cheng Y, Yu S, Lo H. Effects of hyperbaric oxygen therapy on circulating interleukin-8, nitric oxide, and insulin-like growth factors in patients with type 2 diabetes mellitus. *Clin Biochem* 2007; 40: 30–6.
99. Haley D. *Hyperbaric oxygen therapy - recent findings on evidence for its effectiveness*. Alberta: Alberta Heritage Foundation for Medical Research, 2003.
100. Cianci P. Advances in the treatment of the diabetic foot: is there a role for adjunctive hyperbaric oxygen therapy. *Wound Rep Reg* 2004; 12: 2–10.
101. Shuren J, Dei Cas R, Kucken L, Tillman K. Centers for Medicare and Medicaid Services: hyperbaric oxygen therapy in the treatment of hypoxic wounds and diabetic wounds of the lower extremities; 2002.
102. Hopf HW, Ueno C, Aslam R, Burnand K, Fife C, Grant L, Holloway A, Iafrati MD, Mani R, Misare B, Rosen N, Shapshak D, Benjamin Slade J Jr., West J, Barbul A. Guidelines for the treatment of arterial insufficiency ulcers. *Wound Rep Reg* 2006; 14: 693–710.
103. Hyperbaric oxygen therapy for the treatment of non-healing, refractory wounds in non-diabetic patients and refractory soft tissue radiation injuries. Medical Services Advisory Committee Application 1054; May 2003.
104. Abidia A, Laden G, Kuhan G, Johnson BF, Wilkinson AR, Renwick PM, Masson EA, McCollum PT. The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled trial. *Eur J Vasc Endovasc Surg* 2003; 25: 513–8.
105. Hammarlund C, Sundberg T. Hyperbaric oxygen reduced size of chronic leg ulcers: a randomised double-blind study. *Plast Reconstr Surg* 1994; 93: 829–34.